TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Santen Pharmaceutical Co ( (JP:4536) ).
Santen Pharmaceutical Co. has announced the suspension of its planned disposal of treasury shares for a performance-linked stock remuneration plan due to the aggregate amount exceeding 100 million yen. The company has withdrawn its previous securities notice and will provide further details once the Board of Directors finalizes their decisions.
The most recent analyst rating on (JP:4536) stock is a Buy with a Yen2600.00 price target. To see the full list of analyst forecasts on Santen Pharmaceutical Co stock, see the JP:4536 Stock Forecast page.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a specialized company focused on eye health, providing products and services to patients, consumers, and medical professionals globally. With over 130 years of experience, Santen is engaged in research, development, manufacturing, and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries.
Average Trading Volume: 1,398,379
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen559.8B
For an in-depth examination of 4536 stock, go to TipRanks’ Overview page.